The short version of growth hormone secretagogue fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-26. Anything still debated is marked as such rather than presented as settled.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
| Property | Value | Notes |
|---|---|---|
| Appearance (dry) | White to off-white powder | Lyophilized material |
| Solubility | Soluble in water and aqueous buffer | Depends on pH and ionic strength |
| Storage (dry) | Frozen, desiccated, protected from light | Limits hydrolysis and oxidation |
| Storage (solution) | Cold, divided into single-use aliquots | Reduces freeze-thaw exposure |
| Identity method | Mass spectrometry | Confirms expected molecular mass |
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Photorespiration (also known as the oxidative photosynthetic carbon cycle or C2 cycle) refers to a process in plant metabolism where the enzyme RuBisCO oxygenates ribulose 1,5-bisphosphate (RuBP), wasting some of the energy produced by photosynthesis. The desired reaction is the addition of carbon dioxide to RuBP (carboxylation), a key step in the Calvin–Benson cycle, but approximately 25% of reactions by RuBisCO instead add oxygen to RuBP (oxygenation), creating a product that cannot be used within the Calvin–Benson cycle. This process lowers the efficiency of photosynthesis, potentially lowering photosynthetic output by 25% in C3 plants. Photorespiration involves a complex network of enzyme reactions that exchange metabolites between chloroplasts, leaf peroxisomes and mitochondria. The oxygenation reaction of RuBisCO is a wasteful process because 3-phosphoglycerate is created at a lower rate and higher metabolic cost compared with RuBP carboxylase activity. While photorespiratory carbon cycling results in the formation of G3P eventually, around 25% of carbon fixed by photorespiration is re-released as CO2 and nitrogen, as ammonia. Ammonia must then be detoxified at a substantial cost to the cell. Photorespiration also incurs a direct cost of one ATP and one NAD(P)H. While it is common to refer to the entire process as photorespiration, technically the term refers only to the metabolic network which acts to rescue the products of the oxygenation reaction (phosphoglycolate).
== Source text == The source of the contents will be mentioned as follows on Wikipedia articles included under the scope of this project: This article incorporates text from a free content work. Licensed under CC BY 4.0. Text taken from Anatomy and Physiology, J. Gordon Betts et al, Openstax. https://openstax.org/books/anatomy-and-physiology/pages/4-1-types-of-tissues.
== Advertising controversy == In November 1996, a British television advert for Brylcreem shampoo was banned by the Independent Television Commission (ITC) after receiving a letter from a viewer that said it had triggered an epileptic fit in them, as well as a letter from another viewer fearing that epileptic fits would occur from viewing the advert. The commercial featured a man's experience of a nightclub with flashing strobe lights. The ITC, who enforced guidelines to protect viewers with epilepsy, found that the advert did not meet these guidelines.
Sources: en.wikipedia.org
==== Other ==== A defibrillator, an electric device connected to the heart and surgically inserted under the skin, may be recommended. This is particularly if there are any ongoing signs of heart failure, with a low left ventricular ejection fraction and a New York Heart Association grade II or III after 40 days of the infarction. Defibrillators detect potentially fatal arrhythmia and deliver an electrical shock to the person to depolarize a critical mass of the heart muscle.
== History == Spotlight Innovation Inc. was founded in 2012 as Spotlight Innovation, LLC. It became its current iteration in December 2013 after a merger with American Exploration Corp. (AEXP), which had been founded in 2006. At the time of the merger, the new entity, Spotlight Innovation Inc., named Cristopher Grunewald the chief executive officer. The Financial Industry Regulatory Authority approved the name change and the merger on December 16, 2013. Spotlight Innovation began trading on the OTCQB marketplace as STLT in January 2014. In May 2017, Spotlight Innovation announced that Mr. Grunewald had resigned as CEO and that John Krohn, the company's President and Chief Operating Officer, had been appointed as the interim CEO. In 2014, Spotlight Innovation founded Celtic Biotech Iowa, Inc., as a subsidiary and entered into a share exchange agreement with Celtic Biotech LTD (since rescinded), an Ireland-based pharmaceutical company developing products for the treatment of cancer and pain. According to the terms of the agreement, Celtic Biotech LTD became a subsidiary of Celtic Biotech Iowa, Inc. and was also granted access to Spotlight Innovation's commercialization and business development services. In April 2015, Celtic Biotech Iowa's first product, a formulation developed to facilitate topical delivery of drugs called EPISORB, was registered with the Food and Drug Administration and incorporated into the Pharmacy Benefit Managers database.; In Sept. 2018 the Directors of Celtic Biotech Ltd rescinded its share exchange agreement with Spotlight Innovation for just cause.
== Biosynthesis == Typically to other RiPPs, klebsazolicin is produced in three steps. At the first step, a 47-aa precursor peptide KlpA is synthesized using cellular translation machinery. Then an N-terminal leader peptide serves as a recognition element for KlpBCD, a heterocyclase-dehydrogenase complex which converts serine and cysteine residues of KlpA into oxazole and thiazole heterocycles. Finally, the leader is cleaved off by the action of cellular proteases such as TldD/E, and at the same time KlpBCD activates the new N-terminus to form lactamidine. Thus, KlpBCD is able to introduce both azole heterocycles and lactamidine linkages, using side chains of Ser/Cys residues and N-terminal amino group as nucleophiles.
Sources: en.wikipedia.org
=== Treatment approach === Any interventions done are matched with the needs of each individual in an ethical and respected manner. Health belief model encourages increasing individuals' perceived susceptibility to negative health outcomes and making individuals aware of the severity of such negative health behavior outcomes. E.g. through health promotion messages. In addition, the health belief model suggests the need to focus on the benefits of health behaviors and the fact that barriers to action are easily overcome. The theory of planned behavior suggests using persuasive messages for tackling behavioral beliefs to increase the readiness to perform a behavior, called intentions. The theory of planned behavior advocates the need to tackle normative beliefs and control beliefs in any attempt to change behavior. Challenging the normative beliefs is not enough but to follow through the intention with self-efficacy from individual's mastery in problem solving and task completion is important to bring about a positive change. Self efficacy is often cemented through standard persuasive techniques.
VfB Leipzig were immediately successful at their chosen sport and made their way to the first German national championship final held in 1903. Their opponents were DFC Prag, a German-Jewish side from Prague, which was then part of Austria-Hungary. The DFB had invited "German" clubs of this sort from other countries to boost numbers in their new national association. DFC Prag had made their way to the final under circumstances that had allowed them to avoid playing a single playoff match, while VfB Leipzig had come through some hard-fought matches. Arriving in Hamburg for the match, the heavily favoured Pragers took themselves off on an ill-advised pub crawl the night before the contest and so arrived on the pitch in less than ideal match shape. The contest was delayed by half an hour as officials scrambled to find a football that was in good condition. The host, FC 93 Altona Hamburg, provided a new ball, and 11 minutes in, DFC Prag scored the first goal. At the end of the first half, the score stood at 1–1, but VfB Leipzig then pulled away to emerge as the first winners of the Viktoria Meisterschaftstrophäe ("Victoria Championship Trophy"), representative of German football supremacy, on the strength of a decisive 7–2 victory. VfB Leipzig played themselves into another final appearance in 1904, but the match was never contested. A protest by FV Karlsruhe over their disputed semi-final with Britannia Berlin was never resolved, and the DFB called off the final only hours before its scheduled start. There would be no champion that year.
2 parts bai zhi (Chinese:白芷，Angelica dahurica); 2 parts cao wu (Chinese:草烏，Aconitum sp., monkshood or wolfsbane); 2 parts chuān ban xia (Pinellia ternata); 2 parts chuān xiōng (Ligusticum wallichii, Cnidium rhizome, Cnidium officinale or Szechuan lovage); 2 parts dong quai (Angelica sinensis or female ginseng); 1 part tian nan xing (Arisaema rhizomatum or cobra lily) 8 parts yang jin hua (Datura stramonium, Korean morning glory, thorn apple, jimson weed, devil's trumpet, stinkweed, or locoweed). The active ingredients in tsūsensan are scopolamine, hyoscyamine, atropine, aconitine and angelicotoxin. When consumed in sufficient quantity, tsūsensan produces a state of general anesthesia and skeletal muscle paralysis. Shutei Nakagawa (1773–1850), a close friend of Hanaoka, wrote a small pamphlet titled "Mayaku-ko" ("narcotic powder") in 1796. Although the original manuscript was lost in a fire in 1867, this brochure described the current state of Hanaoka's research on general anesthesia. On 13 October 1804, Hanaoka performed a partial mastectomy for breast cancer on a 60-year-old woman named Kan Aiya, using tsūsensan as a general anaesthetic. This is generally regarded today as the first reliable documentation of an operation to be performed under general anesthesia. Hanaoka went on to perform many operations using tsūsensan, including resection of malignant tumors, extraction of bladder stones, and extremity amputations. Before his death in 1835, Hanaoka performed more than 150 operations for breast cancer.
Sources: en.wikipedia.org
Dry powder is typically kept frozen, desiccated, and protected from light. Avoiding moisture exposure and large temperature swings helps slow degradation. Storage recommendations vary by supplier and should be followed for the specific material.
Repeated freezing and thawing can cause peptide aggregation and adsorption to container surfaces, reducing the amount of intact material. It may also accelerate other degradation pathways. Dividing a solution into single-use portions limits the number of cycles a sample experiences.
Reverse-phase liquid chromatography is used to assess purity, while mass spectrometry confirms molecular mass and detects structural modifications. The two methods are complementary. Purity figures are only comparable when analytical conditions and reference standards are specified.
Purity is commonly estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection. Mass spectrometry is used to confirm identity and to detect sequence-related impurities. Reported percentages depend on the method and the impurity threshold used.